Zobrazeno 1 - 10
of 695
pro vyhledávání: '"Daniel J George"'
Autor:
Tian Zhang, Carl Morrison, Sarabjot Pabla, Jason Zhu, Matthew Zibelman, Shannon McCall, Sean T Glenn, Saby George, Yong Hee Lee, Landon C Brown, Chester Kao, Matthew K Labriola, Rajan T Gupta, Daniel J George, Laura J Tafe, Farshid Dayyani, Kunal Desai, Moshe C Ornstein, Emily Kinsey, Jennifer Tran, Konstantin H Dragnev, Mary K Nesline
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background Immunotherapy combinations including ipilimumab and nivolumab are now the standard of care for untreated metastatic renal cell carcinoma (mRCC). Biomarkers of response are lacking to predict patients who will have a favorable or unfavorabl
Externí odkaz:
https://doaj.org/article/9b968140c98748eb94a5b6265a763e29
Autor:
Scott S Tykodi, Daniel J George, Jeff Yorio, Lucio N Gordan, Joshua Zhang, Jennifer L Johansen, Arash Rezazadeh Kalebasty, David R Spigel, Samith T Kochuparambil, Ana M Molina, Heidi McKean, Nishan Tchekmedyian, Margarita Askelson, Thomas E Hutson
Publikováno v:
BMJ Open, Vol 12, Iss 9 (2022)
Objectives The non-randomised, open-label, phase IIIb/IV multicohort CheckMate 920 trial explored the safety and efficacy with a less frequent, but continual nivolumab plus ipilimumab (NIVO+IPI) dosing regimen (cohort 1) to determine whether this mod
Externí odkaz:
https://doaj.org/article/a35e5923581b4b07b7b03b97b3b2d842
Autor:
Thomas Hutson, Peter Van Veldhuizen, Michael R Harrison, Scott S Tykodi, Daniel J George, Lucio N Gordan, Robert S Alter, Edward Arrowsmith, Ivor Percent, Rakesh Singal, Joshua Zhang, Jesus Zoco, Jennifer L Johansen, Arash Rezazadeh Kalebasty
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Background CheckMate 920 (NCT02982954) is a multicohort, phase 3b/4 clinical trial of nivolumab plus ipilimumab treatment in predominantly US community-based patients with previously untreated advanced renal cell carcinoma (RCC) and clinical features
Externí odkaz:
https://doaj.org/article/2afaa38ab63544b783e82c3073c180bf
Autor:
Ramy Sedhom, Santosh Gupta, Yuan Wu, Jason Zhu, Daniele Marin, Michael R Harrison, Landon C Brown, Matthew D Tucker, Eric B Schwartz, Chester Kao, Matthew K Labriola, Rajan T Gupta, Daniel J George, Emmanuel S Antonarakis, Andrew J Armstrong
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Low-density lipoprotein receptor-related protein 1b (encoded by LRP1B) is a putative tumor suppressor, and preliminary evidence suggests LRP1B-mutated cancers may have improved outcomes with immune checkpoint inhibitors (ICI).Methods We co
Externí odkaz:
https://doaj.org/article/f6c317e45ad243c18c3fdb3ae41b8601
Autor:
Andrew J Armstrong, Santosh Gupta, Patrick Healy, Gabor Kemeny, Beth Leith, Michael R Zalutsky, Charles Spritzer, Catrin Davies, Colin Rothwell, Kathryn Ware, Jason A Somarelli, Kris Wood, Thomas Ribar, Paraskevi Giannakakou, Jiaren Zhang, Drew Gerber, Monika Anand, Wen-Chi Foo, Susan Halabi, Simon G Gregory, Daniel J George
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0216934 (2019)
BackgroundRadium-223 is a targeted alpha-particle therapy that improves survival in men with metastatic castration resistant prostate cancer (mCRPC), particularly in men with elevated serum levels of bone alkaline phosphatase (B-ALP). We hypothesized
Externí odkaz:
https://doaj.org/article/a30bb6a9379947f68513ccbaae968fe8
Autor:
Amy E. Leader, Timothy R. Rebbeck, William K. Oh, Alpa V. Patel, Eric P. Winer, LeeAnn O. Bailey, Leonard G. Gomella, Crystal Y. Lumpkins, Isla P. Garraway, Lisa B. Aiello, Monica L. Baskin, Heather H. Cheng, Kathleen A. Cooney, Amanda Ganzak, Daniel J. George, Susan Halabi, Feighanne Hathaway, Claire Healy, Joseph W. Kim, Michael S. Leapman, Stacy Loeb, Kara N. Maxwell, Christopher McNair, Todd M. Morgan, Breanne Prindeville, Howard R. Soule, Whitney L. Steward, Sakinah C. Suttiratana, Mary-Ellen Taplin, Kosj Yamoah, Thierry Fortune, Kris Bennett, Joshua Blanding-Godbolt, Laura Gross, Veda N. Giri
Publikováno v:
BMC Public Health, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Black men consistently have higher rates of prostate cancer (PCA)- related mortality. Advances in PCA treatment, screening, and hereditary cancer assessment center around germline testing (GT). Of concern is the significant under-
Externí odkaz:
https://doaj.org/article/7a481f2b8f7f4858987d88a4639dee1d
Autor:
Elle C. Moore, Gerard C. Blobe, Nicholas C. DeVito, Brent A. Hanks, Michael R. Harrison, Christopher J. Hoimes, Jingquan Jia, Michael A. Morse, Parvathy Jayaprakasan, Andrew MacKelfresh, Hillary Mulder, Adam J. Hockenberry, Alia Zander, Martin C. Stumpe, Jackson Michuda, Kyle A. Beauchamp, Eric Perakslis, Timothy Taxter, Daniel J. George
Publikováno v:
Cancer Medicine, Vol 12, Iss 19, Pp 19394-19405 (2023)
Abstract Background Roughly 5% of metastatic cancers present with uncertain origin, for which molecular classification could influence subsequent management; however, prior studies of molecular diagnostic classifiers have reported mixed results with
Externí odkaz:
https://doaj.org/article/b59390dd42bb4274953a6323c81735b6
Autor:
Zoe D. Michael, Srinath Kotamarti, Rohith Arcot, Kostantinos Morris, Anand Shah, John Anderson, Andrew J. Armstrong, Rajan T. Gupta, Steven Patierno, Nadine J. Barrett, Daniel J. George, Glenn M. Preminger, Judd W. Moul, Kevin C. Oeffinger, Kevin Shah, Thomas J. Polascik
Publikováno v:
The World Journal of Men's Health, Vol 41, Iss 3, Pp 631-639 (2023)
Purpose: Prostate cancer (PCa) screening can lead to potential over-diagnosis/over-treatment of indolent cancers. There is a need to optimize practices to better risk-stratify patients. We examined initial longitudinal outcomes of mid-life men with
Externí odkaz:
https://doaj.org/article/dcb8b48249704eb5a9f6ba4e180b1147
Autor:
Daniel J. George, Ateesha F. Mohamed, Jui‐Hua Tsai, Milad Karimi, Ning Ning, Sayeli Jayade, Marc Botteman
Publikováno v:
Cancer Medicine, Vol 12, Iss 5, Pp 6040-6055 (2023)
Abstract Background Understanding how patients perceive the efficacy, safety, and administrative burden of treatments for metastatic castration‐resistant prostate cancer (mCRPC) can facilitate shared‐decision making for optimal management. This s
Externí odkaz:
https://doaj.org/article/0df60e696c614729bec421b7b4f6be72
Autor:
William Butler, Colin McDowell, Qing Yang, Yiping He, Yue Zhao, J. Spencer Hauck, Yinglu Zhou, Hong Zhang, Andrew J. Armstrong, Daniel J. George, Richard Drake, Jiaoti Huang
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-10 (2023)
Abstract An understanding of the molecular features associated with prostate cancer progression (PCa) and resistance to hormonal therapy is crucial for the identification of new targets that can be utilized to treat advanced disease and prolong patie
Externí odkaz:
https://doaj.org/article/14d23108c7ff44d882b275eaeb03c44d